Warner Chilcott PLC (WCRX): Today's Featured Health Care Loser
Warner Chilcott (WCRX) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.3%. By the end of trading, Warner Chilcott fell 32 cents (-1.6%) to $20.12 on average volume. Throughout the day, 2.8 million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 3.2 million shares. The stock ranged in price between $19.92-$20.51 after having opened the day at $20.44 as compared to the previous trading day's close of $20.44. Other company's within the Health Care sector that declined today were: MediciNova (MNOV), down 42.9%, Catalyst Pharmaceutical Partners (CPRX), down 34.5%, Urologix (ULGX), down 13.7%, and Senesco Technologies (SNT), down 9.3%. Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $5.03 billion and is part of the drugs industry. The company has a P/E ratio of 13.3, below the average drugs industry P/E ratio of 16.6 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and four rate it a hold. TheStreet Ratings rates Warner Chilcott as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.
- You can view the full Warner Chilcott Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV